News

15th February 2018

article written by
Cell Medica

Cell Medica announces the appointment of Kevin Boyle as Chief Financial Officer to head up the Company’s international financial activities   Cell Medica, a leader in cellular immunotherapy for the treatment of cancer, announced today the appointment of Kevin S. Boyle, Sr. as Chief Financial Officer, based in Houston, TX. With over 20 years of financial […]

7th December 2017

article written by
Cell Medica

Dr Annalisa Jenkins is a life sciences business and thought leader with over 25 years of biopharmaceutical industry experience in advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. Prior to joining Cell Medica, Dr Jenkins served as President and CEO of Dimension Therapeutics, a leading gene therapy company […]

18th September 2017

article written by
Cell Medica

Cell Medica Announces the appointment of Luis Borges, PhD, as Chief Scientific Officer (CSO) to accelerate R&D for CAR and TCR programmes Luis Borges, CSO will spearhead the Company’s global research group, including teams in London, Zurich and Houston. Luis brings extensive knowledge of cancer immunotherapy from twenty years of experience in the field, including […]

20th June 2017

article written by
Cell Medica

Cell Medica acquires WT1 cancer immunotherapy from Cell and Gene Therapy Catapult Acquisition transfers rights for WT1-TCR cell therapy from CGT Catapult to Cell Medica Collaboration for development, scale-up and manufacturing also established London, 20 June 2017 – Cell Medica today announced the acquisition of Catapult Therapy TCR Limited, a subsidiary of Cell and Gene […]